



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ofori-Asenso, R;Sahle, BW;Chin, KL;Mazidi, M;Ademi, Z;De Bruin, ML;Liew, D

Title:

Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis

Date:

2021-01-01

Citation:

Ofori-Asenso, R., Sahle, B. W., Chin, K. L., Mazidi, M., Ademi, Z., De Bruin, M. L. & Liew, D. (2021). Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis. *Diabetes Metabolism Research and Reviews*, 37 (1), <https://doi.org/10.1002/dmrr.3350>.

Persistent Link:

<https://hdl.handle.net/11343/275937>

Ofori-Asenso Richard (Orcid ID: 0000-0002-6643-3269)

Manuscript ID: DMRR-19-RES-574

**Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real world settings: evidence from a systematic review and meta-analysis**

*Running title: Real world use of SGLT2 inhibitors*

Richard Ofori-Asenso, PhD;<sup>1,2\*</sup> Berhe W. Sahle, PhD;<sup>3+</sup> Ken Lee Chin, PhD;<sup>2,4+</sup> Mohsen Mazidi, PhD<sup>5</sup>;  
Zanfina Ademi, PhD;<sup>2</sup> Marie Louise De Bruin, PhD;<sup>1</sup> Danny Liew, PhD<sup>2</sup>

<sup>+</sup>These authors contributed equally

<sup>1</sup>Copenhagen Centre for Regulatory Science (CORS), Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Denmark

<sup>2</sup>Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

<sup>3</sup>Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia

<sup>4</sup>Melbourne Medical School, University of Melbourne, Parkville, Victoria, Australia

<sup>5</sup>Department of Twin Research and Genetic Epidemiology, Kings College London, United Kingdom

**\*Address correspondence to:**

Richard Ofori-Asenso, PhD

Department of Pharmacy

Faculty of Health and Medical Sciences,

University of Copenhagen, Universitetsparken 2

Copenhagen, Denmark

Email: richard.ofori-asenso@sund.ku.dk

Tel: +4535332395

Abstract word count: 250

Word count (main text): 3075

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/dmrr.3350](https://doi.org/10.1002/dmrr.3350)

No. of figures: 1

No. of Tables: 2

Supplemental Figures: 2

Supplemental Tables: 7

## **DECLARATIONS**

### **Acknowledgments**

None

### **Conflict of Interest Statement**

DL reports past participation in advisory boards and/or receiving honoraria from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, and Shire for work unrelated to this study. RO and MLDB are employees of The Copenhagen Centre for Regulatory Sciences (CORS). CORS is a cross-faculty university anchored institution involving various public (Danish Medicines Agency, Copenhagen University) and private stakeholders (Novo Nordisk, Lundbeck, Ferring pharmaceuticals, LEO pharma) as well as patient organisations (Rare Diseases Denmark). The center is purely devoted to the scientific aspects of the regulatory field and with a patient-oriented focus and the research is not company-specific product or directly company related and has received funding from Novo Nordisk, Ferring Pharmaceuticals, LEO pharma and Lundbeck for projects not related to this study. All others declare no relevant conflicts of interest.

### **Authors' Contribution Statement**

RO conceived and designed the study. RO, BSW, and KLC performed data extraction and analysis. RO, BSW, KLC, MM, ZA, MLDB, and DL contributed to manuscript preparation and revision for intellectual content. All authors approved the final version before submission.

### **Funding**

No funding or sponsorship was received for this study or publication of this article.

## ABSTRACT

**Aims:** Despite increasing prescription of sodium glucose co-transporter 2 (SGLT2) inhibitors, there is limited insight of the patterns of use among patients with diabetes prescribed these drugs. This study aimed to summarize available real-world data on the adherence and persistence to SGLT2 inhibitors.

**Materials and Methods:** A systematic review for observational studies reporting the adherence and persistence to SGLT2 inhibitors was performed in Medline, Embase, and Web of Science from their inception to October 2019. Data were analyzed via random-effects meta-analysis.

**Results:** A total of 22 studies (31 cohorts) comprising of 123,854 individuals prescribed SGLT2 inhibitors from eight countries were included. The pooled mean proportions of days covered [PDC] at six months and one year were 0.77 (95% confidence interval [CI] 0.72-0.82) and 0.72 (95% CI 0.66-0.77), respectively. The pooled proportions adherent (PDC  $\geq$ 0.80) at six months and one year were 59.5% (95% CI 52.9-65.9) and 49.0% (95% CI 42.3-55.8), respectively. The pooled proportions of people persistent at six months, one year, and two years were 80.1% (95% CI 75.8-84.0), 61.8% (95% CI 57.8-65.7), and 45.9% (95% CI 35.5-56.5), respectively. When persistence was defined as absence of  $\geq$ 90-days gap, the equivalent pooled proportions persistent were 81.5% (95% CI 73.1-88.6), 58.9% (95% CI 53.1-64.6), and 34.7% (95% CI 33.6-35.8). Data from the United States suggested higher adherence and persistence with canagliflozin compared to dapagliflozin.

**Conclusion:** Real world adherence and persistence to SGLT2 inhibitors is poor. Hence, targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.

**Keywords:** sodium glucose cotransporter 2 inhibitors; SGLT2; adherence, persistence, discontinuation

## INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a major public health issue which is estimated to affect more than 400 million people worldwide (1). Chronic hyperglycemia is a key characteristic of T2DM and is associated with increased risk of micro- and macrovascular complications (2, 3).

Effective blood glucose control is central to the management of T2DM. The American Diabetes Association/European Association for the Study of Diabetes (4) and the American Association of Clinical Endocrinologists (AACE) (5) recommend glycated hemoglobin (HbA<sub>1c</sub>) levels of <7.0% and ≤6.5%, respectively, while also emphasizing the need to individualize treatment goals. Although dietary and lifestyle changes are recommended for patients with T2DM, the majority require pharmacological treatment to achieve the desired glycemic targets (4, 6).

Despite the availability of several antihyperglycemic agents (6, 7), about half of the patients with T2DM do not achieve glycemic targets (8, 9). Thus, there is increasing interest in novel therapeutic options to improve glycemic control in patients with T2DM. Recently, sodium glucose cotransporter 2 (SGLT2) inhibitors have been touted as a ‘game changer’ for the management of T2DM (10). Randomized clinical trials (RCTs) have shown SGLT2 inhibitors to significantly improve glycemic control as well as exert additional pleotropic effects such as reduction in blood pressure and weight in patients with T2DM (11-15). Consequently, increased prescription of SGLT2 inhibitors has been reported in many countries (16-19). However, patients enrolled in RCTs are often highly motivated and usually exhibit higher adherence (i.e., the extent to which patients act in accordance with the prescribed interval, and dose of a dosing regimen (20)) and persistence (i.e., the duration of time from initiation to discontinuation of therapy (20)) to treatment than that observed in routine clinical practice (21, 22). These disparities potentially contribute to poor drug effectiveness observed in real-world settings (22-24).

At present, there is limited insight of the patterns of use of SGLT2 inhibitors among T2DM patients. In particular, McGovern *et al* recently reported a systematic review of the adherence and persistence to different classes of antidiabetic medications (25). However, data on SGLT2 inhibitors were conspicuously missing. Thus, we conducted a systematic review and meta-analysis to summarize the class-level adherence and persistence to SGLT2 inhibitors and to determine if any differences exist across various SGLT2 inhibitors in real world settings.

## **METHODS**

The study was performed according to the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (26), the Meta-analysis of Observational Studies in Epidemiology (27) and the Cochrane Collaboration Handbook (28).

### **Search strategy and study selection**

Electronic searches were performed in Medline, Embase, and Web of Science for observational studies published in English that reported the adherence and persistence to SGLT2 inhibitors. The keywords used included “sodium glucose co-transporter 2 inhibitors OR SGLT2 inhibitors OR individual generic and propriety names” AND “adherence OR persistence OR compliance OR discontinuation” (Supplemental **Table S1**). The search was initially performed on 1 August 2019 and last updated on 24 October 2019. Bibliographic searches of the included studies were also performed. All original research articles reporting on adherence and/or persistence among people dispensed SGLT2 inhibitors were eligible for inclusion. Although the definition of persistence is often variable in the literature (20), similar to other reviews (28), we did not restrict our inclusion to any specific definition. Moreover, studies utilizing any of a variety of methods including pill count, prescription refill records or patient’s self-reports/recalls assessed via validated scales to measure adherence were eligible for inclusion. Two reviewers (RO and BSW) independently performed the searches and reviewed the titles and abstracts of all the articles identified. Any disagreements were resolved with a third reviewer (KLC).

### **Data extraction and quality assessment**

Data were extracted independently by two reviewers (KLC and BWS). For each study, we collected the author details, year, country, participant characteristics, data sources, definition of adherence and persistence, as well as outcome data. If studies assessed adherence using multiple measures, the proportion of days covered (PDC) was preferred as the more robust metric (30). For some studies, persistence at different time points was extracted from Kaplan Meier curves using an online graph digitizer (31). Similar to other drug utilization reviews (25), study quality was assessed using the Newcastle-Ottawa scale for observational studies (NOS) (32). Quality assessments were performed independently by two reviewers (BSW and KLC) and any disagreements were resolved with a third reviewer (RO).

### **Data Analysis**

Where data were available, we estimated the adherence and persistence to SGLT2 inhibitors at specific time points. Overall adherence and persistence estimates were obtained through meta-analysis using the Freeman-Tukey double arcsine transformed proportions to stabilize the variance. We also pooled data on the mean PDC at six months and one year of SGLT2 inhibitors use. For this, the standard error (SE) was calculated as:  $SE = \text{standard deviation (SD)} / \sqrt{\text{sample size}}$ . We pooled persistence data across all studies regardless of definition used. However, we also performed a subgroup analysis by pooling data across studies that defined non-persistence as having a gap of  $\geq 90$  days, as this has been a commonly used metric (20,33,34). Furthermore, if data existed from at least two studies that compared adherence or persistence to individual SGLT2 inhibitors, data were pooled with the effect measure expressed as odds ratio (OR). All meta-analyses were performed using the random-effects model due to the anticipated between-study heterogeneity (34). Statistical heterogeneity was quantified with Cochran's Q test and the

$I^2$  statistic. Publication bias was assessed by funnel plot visualization and statistically evaluated with Egger's test in the event that 10 or more effect sizes were available (28). The robustness of pooled estimates was tested via leave-one-out sensitivity analyses where more than two data points were available (28). A study was considered to be dominant if the pooled effect without it was outside the 95% confidence interval of the overall pooled estimate. Analyses were performed using Stata 16/SE (StataCorp, Texas, USA) and a  $p$ -value  $<0.05$  was considered statistically significant.

## RESULTS

A total of 1385 articles were retrieved from the database searches, of which 53 were subjected to full-text assessment after removal of duplicates and titles and abstract screening. Subsequently, 20 articles were selected for inclusion. Two additional articles were retrieved via reference screening, resulting in 22 studies (involving 31 cohorts) being included in the review (**Figure 1**) (36-57). The descriptive characteristics of the studies are presented in **Table 1**. The included studies, which comprised 123,854 individuals prescribed SGLT2 inhibitors, were published from 2015 to 2019 and were from eight different countries: Australia ( $n=1$ ), Taiwan ( $n=1$ ), Canada ( $n=1$ ), UK ( $n=2$ ), Hungary ( $n=1$ ), Pakistan ( $n=1$ ), Italy ( $n=2$ ) and USA ( $n=13$ ). The median sample size across the included studies was 1981 (interquartile range [IQR] 706-8609). The included studies were of reasonable quality with the median NOS score being 8 (IQR 7-8) (supplemental **Table S2**).

### Adherence to SGLT2 inhibitors

Adherence to SGLT2 inhibitors was reported in 12 studies. Of these, only one did not assess the PDC. In the study which did not assess PDC, participants were followed for only two months and 76.9% were reported to be adherent (48). Among five studies (eight cohorts) involving 38,684 individuals, the mean PDC at six months ranged from 0.65 to 0.86. The pooled six-month mean PDC among people prescribed SGLT2 inhibitors was 0.77 (95% CI 0.72-0.82;  $I^2=99.6%$ ) (Supplemental **Figure S1**). Four studies (seven cohorts) involving 34,667 individuals reported that 41.0-76.3% of people were adherent (PDC  $\geq 0.80$ ) to SGLT2 inhibitors at six months. The pooled proportion adherent at six months was 59.5% (95% CI 52.9-65.9;  $I^2=99.2%$ ) (Supplemental **Figure S2**). Across five studies (10 cohorts) involving 28,939 individuals, the reported mean PDC at one year was within the range 0.58-0.81. The pooled mean PDC at one year was 0.72 (95% CI 0.66-0.77;  $I^2=99.2%$ ) (Supplemental **Figure S3**). In five studies (10 cohorts), 29.9-69.4% of people were reported to be adherent (PDC  $\geq 0.80$ ) at one year. The pooled proportion of people adherent to SGLT2 inhibitors at one year was 49.0% (95% CI 42.3-55.8) (Supplemental **Figure S4**).

### **Persistence to SGLT2 inhibitors**

A total of 16 studies reported data on non-persistence with SGLT2 inhibitors. However, the definition of non-persistence varied across studies. Three studies defined non-persistence as a gap of  $\geq 60$  days (34, 36, 41), one study used a gap of  $\geq 180$  days (49), seven studies defined non-persistence as a gap of  $\geq 90$  days (39, 40, 43, 51-53, 55) and five used other definitions (44-46, 50, 54). Nine studies (10 cohorts) involving 80,894 individuals reported that 72.5-95.7% were persistent to SGLT2 inhibitors at six months. The pooled proportion persistent to SGLT2 inhibitors at six months across these studies was 80.1% (95% CI 75.8-84.0;  $I^2=99.4%$ ) (Supplemental **Figure S5**). In three studies (four cohorts) involving 19,163 individuals which defined non-persistence as a gap of  $\geq 90$  days, the pooled proportion persistent at six

months was 81.5% (95% CI 73.1-88.6;  $I^2=99.5\%$ ). Ten studies (16 cohorts) involving 79,181 individuals reported that 40.0-82.1% were persistent at one year. The pooled proportion persistent to SGLT2 inhibitors at one year across these studies was 61.8% (95% CI 57.8-65.7;  $I^2=99.2\%$ ) (Supplemental **Figure S6**). In six studies (11 cohorts) involving 33,729 individuals which defined non-persistence as a gap of  $\geq 90$  days, the pooled proportion persistent at one year was 58.9% (95% CI 53.1-64.6;  $I^2=99.1\%$ ). Four studies (five cohorts) involving 51,510 individuals reported that 29.1-56.8% were persistent to SGLT2 inhibitors at two years. The pooled proportion persistent at two years across these studies was 45.9% (95% CI 35.5-56.5;  $I^2=99.8\%$ ) (Supplemental **Figure S7**). In two studies (two cohorts) involving 7182 individuals which defined non-persistence as a gap of  $\geq 90$  days, the pooled proportion persistent at two years was 34.7% (95% CI 33.6-35.8;  $I^2=0.0\%$ ).

### Comparisons of different SGLT2 inhibitors

Only one study conducted among Australians compared adherence and persistence between people prescribed empagliflozin and dapagliflozin (52). In this study, empagliflozin was associated with a greater likelihood of being adherent (PDC  $\geq 0.80$ ) (adjusted OR 1.39, 95% CI 1.29-1.51) or persistent (no gap of  $\geq 90$ -days) (adjusted hazard ratio [HR] 1.14, 95% CI 1.06–1.22) compared to dapagliflozin. Three US-based studies involving a total of 14,932 individuals compared adherence between canagliflozin and dapagliflozin (35, 39, 40). Pooled data from these studies suggested that canagliflozin was associated with higher likelihood of being adherent (PDC  $\geq 0.80$ ) (OR 2.00, 95% CI 1.68-2.40;  $I^2=78.0\%$ ) compared to dapagliflozin (Supplemental **Table S12**). Moreover, in two US studies involving 13,816 individuals, pooled data suggested higher persistence (no-gap of  $\geq 90$  days) with canagliflozin compared to dapagliflozin (OR 1.94, 95% CI 1.24-3.04;  $I^2=96.8\%$ ). One study found no significant difference in

adherence between canagliflozin 100mg and 300 mg (one-year adherence [PDC  $\geq$ 0.80] rate; canagliflozin 100mg=49.0%, canagliflozin 300mg, 51.5%;  $p$ -value for difference=0.065) (39).

Similarly, pooled data from two studies involving 14,856 individuals showed that canagliflozin 100mg was not associated with higher persistence (no-gap of  $\geq$ 90 days) compared to canagliflozin 300mg (OR 0.94, 95% CI 0.88-1.01;  $I^2$ =0.0%).

### **Sensitivity analyses and assessment of publications bias**

In all the estimates involving three or more effect sizes, a leave-one-out sensitivity analysis did not significantly change the pooled results. We also visually inspected funnel plot asymmetry and quantified with Egger's test to detect publication bias for pooled estimates based on 10 or more effect sizes. For all of these analyses, Egger's tests were not statistically significant (proportion adherent at one year,  $p$ =0.120; proportion persistent at six months [all definitions],  $p$ =0.216; proportion persistent at one year [all definitions],  $p$ =0.184; proportion persistent at one year [ $\geq$ 90-days gap],  $p$ =0.09). These results suggested no evidence of publication bias.

### **DISCUSSION**

In this systematic review and meta-analysis, we summarized the available real-world data on the adherence and persistence to SGLT2 inhibitors. We found that about 60% and <50% of the patients prescribed SGLT2 inhibitors were adherent at six months and one year, respectively. Moreover, 80%, 62%, and 46% of SGLT2 inhibitors users were persistent at six months, one year, and two years, respectively. Adherence and persistence rates varied across different SGLT2 inhibitors.

The insulin-independent effect of SGLT2 inhibitors is associated with a low risk of hypoglycemia, which makes them attractive for the management of patients with T2DM (58, 59). Data from several RCTs have shown SGLT2 inhibitors to improve glycemic control among patients with T2DM (58, 60, 61).

Furthermore, SGLT2 inhibitors have also been shown to significantly reduce the risk of cardiovascular disease (CVD) and mortality. In the Canagliflozin cardiovascular assessment study (CANVAS), canagliflozin was associated with a 14% risk reduction (HR 0.86, 95% CI 0.75-0.97) in the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo over a median duration of 2.4 years (62). Similarly, the results of the EMPA-REG Outcome trial suggested that empagliflozin led to a 12–15% increase in life expectancy regardless of age, representing a prolongation of life span by, on average, 2.5 years (13). Furthermore, the DECLARE-TIMI 58 showed that dapagliflozin reduced hospitalization for heart failure and appeared to slow the loss of kidney function (63). Similar renal benefits of SGLT2 inhibitors have also been demonstrated in the CREDENCE (Evaluation of the effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy) and EMPAG-REG Renal studies (64, 65). These positive outcomes associated with SGLT2 inhibitors in RCTs have resulted in their increased use in many countries (17, 18). For example, in Australia, the number of patients dispensed SGLT2 inhibitors increased about eight-fold between June 2014 and June 2016 (19). In the United States, the uptake of SGLT2 inhibitors increased more than five-fold (from 0.8% to 4.4%) between 2014 and 2015 (16).

The RCT-demonstrated benefits of SGLT2 inhibitors have been observed against a background of high treatment adherence and persistence. In trials of SGLT2 inhibitors, about 70-80% of patients were persistent with treatment for more than two years of follow-up (13, 62, 63). However, our meta-analysis

based on data from real world settings suggests significantly lower persistence, with <50% of patients being persistent with treatment at two years. The lower persistence in real world settings could contribute to poor drug effectiveness and hamper the realization of the effects of SGLT2 inhibitors demonstrated within trial settings. For example, a US study involving adult commercial and Medicare Advantage health plan enrollees found that those adherent to SGLT2 inhibitors experienced larger reductions in glycated hemoglobin (HbA1c) than non-adherent individuals (1.17% versus 0.73%,  $p < 0.001$ ) (38). Moreover, non-adherent individuals increased insulin use by 5.4% in the follow-up period whereas there was no change in insulin use among people adherent to SGLT2 inhibitors.

To optimize the clinical use of SGLT2 inhibitors, Vardeny and Vaduganathan recently published a practical guide for clinicians in which they emphasized key areas including pre-initiation safety screening, selecting an appropriate drug and starting dose, patient counselling, tracking of adherence, and monitoring for adverse effects (66). For adverse effects of SGLT2 inhibitors, the most common one appears to be genital infections, the risk of which was increased up to four-fold in RCTs (67). Recently, Gutiérrez Lorenzo *et al* reported that of the patients who discontinued SGLT2 inhibitors in their Italian cohort, 57% were due to genital and urinary tract infections, whereas 30% were due to other medication-related adverse events (47). Thus, educating patients on measures to minimize these risks could improve adherence and treatment persistence. For example, to reduce the risk of genital infections, counseling about maintenance of perineal hygiene should be included in all diabetes education sessions (68). Moreover, because SGLT2 inhibitors create an osmosis diuresis, they may cause intravascular volume depletion and hypotension (59). Thus, patients need to be advised to maintain adequate fluid and

electrolyte intake while at the same time clinicians should be cautious when co-prescribing SGLT2 inhibitors with loop diuretics (66, 68).

Overall, the results of our meta-analysis concur with previous studies which have shown poor adherence and persistence to different T2DM medications in real world settings (25, 67, 70). Thus, greater efforts to identify the determinants and modifiable drivers of poor adherence and persistence are important.

Different interventions including real-time medication monitoring combined with short message service (SMS) (71), those aimed at reducing regimen complexity (72, 73), as well as interventions seeking to improve patient knowledge (e.g., through pharmacist-led integrated management and education programmes) (74) or those providing extended supervisory health services (75) have shown positive effects on treatment adherence and persistence. However, available evidence suggests that multi-factorial interventions that are tailored to patient-specific needs are more likely to provide greater improvements in adherence and persistence compared to unifactorial interventions (72, 76, 77). Our meta-analysis showed a temporal continuous decline in adherence and persistence to SGLT2 inhibitors from six months to two years. Thus, adherence monitoring may need to be implemented as soon as patients commence treatment and should also be an ongoing process and incorporated into patients' routine management plans.

Our systematic review and meta-analysis has limitations that warrant mention. In particular, most studies relied on indirect measures of adherence and it was impossible to ascertain whether the patients prescribed SGLT2 inhibitors actually took the medication. Studies also did not report detailed information as to why patients were non-adherent or non-persistent to SGLT2 inhibitors. For example, adverse events or poor drug effectiveness may contribute to patient- or clinician-initiated treatment discontinuations (78).

More than half of the included studies were also from the United States. While this reflects market entry of SGLT2 inhibitors, the generalizability of our findings could be limited and further studies evaluating the adherence and persistence to SGLT2 inhibitors in other regions are needed. Furthermore, the heterogeneity across the included studies was high, although, potential sources of heterogeneity could not be fully explored through statistical approaches such as meta-regression due to the small number of studies included in individual analysis (28). Also, it is possible that the timing of the publication of the results of the cardiovascular outcome trials of the different SGLT2 inhibitors could potentially influence adherence and persistence patterns, although, the extent of the influence if present could not be quantified. Furthermore, while in some instances patients who may be persistent may not be necessarily adherent (20), we were unable to thoroughly investigate this pattern due to limited data. Lastly, further bias may have arisen from our limitation of component studies to English, although the extent of this bias, if present, would likely have been small. Despite the above limitations, the available real-world data generally suggest sub-optimal adherence and persistence to SGLT2 inhibitors which warrant attention. Large real-world studies have confirmed substantial cardiovascular benefit with the use of SGLT2 inhibitors (79). Hence, addressing issues of poor adherence and persistence could lead to greater benefits for many patients with T2D.

## **CONCLUSION**

This systematic review and meta-analysis identified poor adherence and persistence to SGLT2 inhibitors in real world settings. Thus, potential targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.

## REFERENCES

1. International Diabetes Federation. Diabetes Facts & Figures: IDF; 2019 [Available from: <https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>].
2. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. *Clinical Diabetes*. 2008;26(2):77.
3. Beckman Joshua A, Creager Mark A. Vascular Complications of Diabetes. *Circulation Research*. 2016;118(11):1771-85.
4. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41(12):2669.
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. *Endocr Pract*. 2019;25(1):69-100.
6. Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, et al. Pharmacotherapy of type 2 diabetes: An update. *Metabolism*. 2018;78:13-42.
7. Edelman SV, Polonsky WH. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. *Diabetes Care*. 2017;40(11):1425-32.
8. Ross SA. Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes. *The American Journal of Medicine*. 2013;126(9):S38-S48.
9. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. *Diabetes Ther*. 2017;8(4):863-73.

10. Sharkey N, Maxwell P. WILL SGLT2 INHIBITORS PROVE TO BE A 'MULTIPLE' GAMECHANGER? *Ulster Med J.* 2019;88(1):8-9.
11. Zhou Y, Geng Z, Wang X, Huang Y, Shen L, Wang Y. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. *Diabetes Metab Res Rev.* 2020 Feb;36(2):e3223. doi: 10.1002/dmrr.3223.
12. Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, et al. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. *Cardiovasc Res.* 2019;115(2):266-76.
13. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015;373(22):2117-28.
14. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine.* 2019;380(4):347-57.
15. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes care.* 2013;36(9):2508-15.
16. Raval AD, Vyas A. National Trends in Diabetes Medication Use in the United States: 2008 to 2015. *J Pharm Pract.* 2018;897190018815048.
17. Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, et al. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. *Diabetes, obesity & metabolism.* 2019;21(7):1576-84.

18. Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. *Diabetes Obes Metab*. 2018;20(9):2159-68.
19. Drug utilisation sub-committee (DUSC). Medicines for the treatment of diabetes 2017 [Available from: <http://www.pbs.gov.au/industry/listing/participants/public-release-docs/2017-02/diabetes-dusc-prd-2017-02.pdf>].
20. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. *Value Health*. 2008;11(1):44-7.
21. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". *Lancet*. 2005;365(9453):82-93.
22. Zullig LL, Deschodt M, Liska J, Bosworth HB, De Geest S. Moving from the Trial to the Real World: Improving Medication Adherence Using Insights of Implementation Science. *Annu Rev Pharmacol Toxicol*. 2019;59:423-45.
23. Carls GS, Tuttle E, Tan R-D, Huynh J, Yee J, Edelman SV, et al. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. *Diabetes care*. 2017;40(11):1469-78.
24. Guerci B, Charbonnel B, Gourdy P, Hadjadj S, Hanaire H, Marre M, et al. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. *Diabetes Metab*. 2019;45(6):528-35.
25. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. *Diabetes Obes Metab*. 2018;20(4):1040-3.

26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
27. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008-12.
28. Green S, J H. *Cochrane Handbook of Systematic reviews of interventions* 2005.
29. Ofori-Asenso R, Jakhu A, Zomer E, Curtis AJ, Korhonen MJ, Nelson M, et al. Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. *J Gerontol A Biol Sci Med Sci*. 2018;73(6):813-9.
30. Pharmacy Quality Alliance. Adherence: PQA; 2018 [Available from: [pqaalliance.org/adherence-measures](http://pqaalliance.org/adherence-measures)].
31. Digitizer GG. About 2019 [Available from: <http://getdata-graph-digitizer.com/index.php>].
32. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2014 [Available from: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)].
33. Genberg BL, Rogers WH, Lee Y, et al. Prescriber and pharmacy variation in patient adherence to five medication classes measured using implementation during persistent episodes. *Pharmacoepidemiol Drug Saf*. 2016; 25: 790-7
34. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. *J Manag Care Pharm*. 2009; 15: 728-40
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-60.

36. Bell KF, Cappell K, Liang M, Kong AM. Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas. *American Health and Drug Benefits*. 2017;10(4):165-73.
37. Blonde L, Burudpakdee C, Divino V, Bookhart B, Cai J, Pfeifer M, et al. The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. *Current medical research and opinion*. 2018;34(8):1501-11.
38. Bowen K, Gleason P. Among commercially insured members with diabetes mellitus, choice and persistence of drug therapy: Dipeptidyl peptidase-4 inhibitors versus glucagon-like peptide-1 agonists or sodium-glucose cotransporter-2 inhibitors. *Journal of Managed Care and Specialty Pharmacy*. 2018;24(10 A):S36.
39. Buysman EK, Chow W, Henk HJ, Rupnow MFT. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. *BMC endocrine disorders*. 2015;15:67.
40. Buysman EK, Anderson A, Bacchus S, Ingham M. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. *Advances in therapy*. 2017;34(4):937-53.
41. Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. *Journal of medical economics*. 2016;19(12):1175-86.
42. Cai J, Divino V, Burudpakdee C. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. *Current medical research and opinion*. 2017;33(7):1317-28.

43. Coleman CI, Pandya S, Wang L, Baser O, Cai J, Ingham M, et al. Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. *Journal of comparative effectiveness research*. 2019;8(11):889-905.
44. Chow W, Buysman E, Rupnow MFT, Aguilar R, Henk HJ. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting. *Current medical research and opinion*. 2016;32(1):13-22.
45. Diels J, Neslusan C. Comparative persistency with newer agents used to treat Type 2 Diabetes (T2DM) In the United States: Canagliflozin versus dipeptidyl Peptidase-4 (Dpp-4) inhibitors and glucagon-like Peptide-1 (Glp-1) agonists. *Value in Health*. 2015;18(3):A68-A9.
46. Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, et al. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. *Journal of endocrinological investigation*. 2019.
47. Gutierrez Lorenzo M, Yunquera Romero L, Lorenzo VT, Morales Lara MJ. Discontinuation of sodium-glucose cotransporter 2 inhibitors due to recurrent genitourinary infections. *European Journal of Hospital Pharmacy*. 2018;25(Supplement 1):A47.
48. Htike ZZ, Lin MZ, Davies MJ, Lawrence IG. Real-life initial experience of using dapagliflozin in a university teaching hospital. *Diabetic Medicine*. 2015;32(SUPPL. 1):173.
49. Jain R, Cai J, Fu AC, Chow W, Tan H. Real-world (RW) glycemic control and medication adherence among patients with type 2 diabetes mellitus (T2DM) initiated on canagliflozin. *Diabetes*. 2016;65(Supplement 1):A304-A5.

50. Jamaluddin, Nizamuddin, Khan M, Naz S, Mustafa A, Iqbal W. Compliance in type 2 diabetic patients treated with SGLT2 inhibitors in a tertiary care hospital Peshawar Pakistan. *Medical Forum Monthly*. 2019;30(5):56-8.
51. Jermendy G, Kiss Z, Rokszin G, Abonyi-Toth Z, Wittmann I, Kempler P. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study. *Diabetes Therapy*. 2018;9(5):2133-41.
52. Lin YH, Shao SC, Chan YY, Chen HY, Yang YHK, Lai ECC. Analysis on reasons for discontinuations of sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus in real-world practices in Taiwan. *Pharmacoepidemiology and Drug Safety*. 2018;27(Supplement 2):43.
53. McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S. A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. *Diabetes therapy : research, treatment and education of diabetes and related disorders*. 2018;9(1):229-42.
54. Ofori-Asenso R, Liew D, Lalic S, Mazidi M, Magliano DJ, Ademi Z, et al. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. *Advances in therapy*. 2019.
55. Singhal M, Tan H, Coleman CI, Herman WH, Cai J, Han M, et al. Real-world comparative effectiveness, treatment patterns, and costs in type 2 diabetes mellitus (T2DM) patients initiated on canagliflozin 300 mg (CANA) or a glucagon-like peptide-1 receptor agonist (GLP-1). *Diabetes*. 2018;67(Supplement 1):A345.

56. Woo V, Bell A, Clement M, Camacho F, Georgijev N, Rose JB, et al. CANadian CANagliflozin REgistry (CanCARE): A prospective, observational, assessment of canagliflozin (CANA) treatment in type 2 diabetes; 12 month results. *Diabetologia*. 2018;61(Supplement 1):S309-S10.
57. Wysham CH, Pilon D, Ingham M, Lafeuille M-H, Emond B, Kamstra R, et al. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. *Current medical research and opinion*. 2018;34(6):1125-33.
58. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med*. 2013;159(4):262-74.
59. Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, et al. Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. *Diabetes Ther*. 2017;8(5):953-62.
60. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. *Kidney Int Suppl*. 2011(120):S20-7.
61. Thrasher J. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. *Am J Cardiol*. 2017;120(1S):S4-S16.
62. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erond N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017;377(7):644-57.
63. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *The New England journal of medicine*. 2019;380(4):347-57.

64. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med.* 2019;380(24):2295-306.
65. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med.* 2016;375(4):323-34.
66. Vardeny O, Vaduganathan M. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. *JACC Heart Fail.* 2019;7(2):169-72.
67. Liu J, Li L, Li S, Jia P, Deng K, Chen W, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep.* 2017;7(1):2824.
68. Kalra S, Baruah MP, Sahay R. Medication counselling with sodium glucose transporter 2 inhibitor therapy. *Indian J Endocrinol Metab.* 2014;18(5):597-9.
69. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. *Diabet Med.* 2015;32(6):725-37.
70. Capoccia K, Odegard PS, Letassy N. Medication Adherence With Diabetes Medication: A Systematic Review of the Literature. *Diabetes Educ.* 2016;42(1):34-71.
71. Vervloet M, van Dijk L, de Bakker DH, Souverein PC, Santen-Reestman J, van Vlijmen B, et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. *Diabet Med.* 2014;31(7):821-8.
72. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. *Diabetes Ther.* 2013;4(2):175-94.

73. Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. *Arch Intern Med.* 2011;171(9):814-22.
74. Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. *J Clin Pharm Ther.* 2006;31(5):409-19.
75. Schoenthaler A, Cuffee Y. A systematic review of interventions to improve adherence to diabetes medications within the patient-practitioner interaction. *Journal of Clinical Outcomes Management* 2013;20 (11):494-506.
76. Williams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. *Diabetes Manag (Lond).* 2014;4(1):29-48.
77. Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes--impact on adherence. *PLoS One.* 2015;10(2):e0118296.
78. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. *Front Pharmacol.* 2013;4:91.
79. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. *J Am Coll Cardiol.* 2018; 71: 2628-39.

**Table 1:** Descriptive characteristics of the included studies

Study reference	Country	Population characteristics	Data source(s)	Sample size	Outcomes definition	Outcomes data
Bell et al. (2017) (36)	USA	Adults aged $\geq 18$ years with $\geq 1$ outpatient pharmacy claim between January 1, 2015, and December 31, 2015	Administrative health insurance claims data extracted from the Truven Health MarketScan Commercial Claims and Encounters (Commercial), Medicare Supplemental and Coordination of Benefits (Medicare Supplemental), and Early View databases	17724	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-persistent: gap $>60$ days	Mean PDC at 6 mo: $0.76 \pm 0.28$ % adherent at 6 mo: 61.8% % persistent at 6 mo: 76.4%
Blonde et al. (2018) (37)	USA	Patients with pharmacy claim from 1 January 2014 to 30 September 2016	Optum Clinformatics database	1116 (Canagliflozin=558; Dapagliflozin=558)	Adherence assessed via PDC Adherent: PDC $\geq 0.80$	Mean PDC at 6 mo: canagliflozin: $0.74 \pm 0.26$ dapagliflozin: $0.65 \pm 0.28$ % adherent at 6 mo: canagliflozin: 58.1% dapagliflozin: 41.0%
Bowen and Gleason (2018) (38)	USA	Patients with first claim of diabetes medication between Jan. 1, 2016 and March 31, 2018, and who did not have a preceding claim for any other antihyperglycemic agent other than metformin.	Integrated medical and pharmacy claims for 15 million commercially insured members	17019	Non-persistent: gap $>60$ days	% persistent at 6mo <sup>†</sup> : 69.4% % persistent at 1y: 56.9% % persistent at 2y <sup>†</sup> : 42.7%
Buysman et al. (2015) (39)	USA	Adult patients ( $\geq 18$ years) who had had filled at least one canagliflozin prescription between April and October 2013	Optum Research Database	4017 (Canagliflozin 100mg=2625; Canagliflozin 300mg=1392)	Adherence assessed via PDC	Mean PDC at 6 mo: 74.0
Buysman et al. (2017) (40)	USA	Patients with a pharmacy claim for canagliflozin between April 01, 2013 and August 31, 2014	US administrative claims data from commercial and Medicare Advantage healthcare enrollees	2261	Adherence assessed via PDC Adherent: PDC $\geq 0.80$	Mean PDC at 1y: $0.68 \pm 0.29$ % adherent at 1y: 53.7%
Cai et al. (2016) (41)	USA	Patients with medical and pharmacy claims data from February 1, 2013 to July 31, 2015	Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases	4183 (Canagliflozin 100mg=1659; Canagliflozin 300mg=1266; Dapagliflozin 5mg=846; Dapagliflozin 10mg=412)	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-persistent: gap $\geq 90$ days	Mean PDC at 1y canagliflozin 100mg: 0.67 canagliflozin 300mg: 0.68 dapagliflozin 5mg: 0.55 dapagliflozin 10mg: 0.57 % Adherent at 1y canagliflozin 100mg: 49.0% canagliflozin 300mg: 51.5% dapagliflozin 5mg: 29.9% dapagliflozin 10mg: 31.3% % Persistent at 1y canagliflozin 100mg: 61.0% canagliflozin 300mg: 64.0% dapagliflozin 5mg: 40.0% dapagliflozin 10mg: 41.0%

Cai et al. (2017) (42)	USA	Patients with medical and pharmacy claims data from February 1, 2013 to June 31, 2015	QuintilesIMS PharMetrics and Health Plan Claims Database	9633 (Canagliflozin 6546; Dapagliflozin=3087)	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-persistent: gap $\geq 90$ days	Mean PDC at 1y: Canagliflozin: 0.71 $\pm$ 0.31 Dapagliflozin: 0.64 $\pm$ 0.31 % adherent at 1y: Canagliflozin: 56.2% Dapagliflozin: 41.8% % persistent at 1y: Canagliflozin: 67.6% Dapagliflozin: 57.4%
Coleman et al. (2019) (43)	USA	Patients with at least one dispensation of canagliflozin from 1 January 2013 to 31 March 2015	Optum integrated database	201	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-persistent: gap $> 60$ days	% adherent at 9 mo: 60.1% % persistent at 6 mo <sup>†</sup> : 73.6% % persistent at 9 mo: 72.1%
Chow et al. (2016) (44)	USA	Patients who filled at least one prescription between 1 April 2013 and 31 October 2013	Optum Research Database	3846 (Hispanic/Latino cohort=438; non-Hispanic/Latino cohort=3408)	Adherence assessed via PDC Adherent: PDC $\geq 0.80$	Mean PDC at 6 mo: Hispanic/latino cohort: 0.70 Non-Hispanic/latino: 0.74 % adherent at 6 mo: Hispanic/latino cohort: 50.0% Non-Hispanic/latino: 58.0%
Diels and Neslusan (2015) (45)	USA	Patients dispensed canagliflozin in 2013	Optum and Truven databases	11931 (canagliflozin 100mg=7445; canagliflozin 300mg=4486)	Non-persistent: $\geq 90$ days	% persistent at 1y: Canagliflozin 100mg: 64.0% Canagliflozin 300mg: 65.0%
Fadini et al. (2019) (46)	Italy	Patients who were initiated on dapagliflozin in 2015-2016	The DARWIN-T2D multicenter retrospective study conducted at diabetes specialist outpatient clinics	1701	N.S	% persistent at 3-12 mo: 48.9%
Gutiérrez Lorenzo et al. (2018) (47)	Italy	Patients with record of SGLT2 prescription for at least 6 months	Local hospital record	691	Non-persistent: patients who interrupted treatment	% Persistent at 6 mo: 95.7%
Htike et al (2015) (48)	UK	Patients treated with dapagliflozin at a university hospital	Hospital electronic and paper records	44	N.S	% persistent at 6 mo: 73.0%
Jain et al. (2016) (49)	USA	Adult patients who received the first canagliflozin claim between 1 April 2013 and 30 April 2014	HealthCore Integrated Research Database	881	Adherence assessed via PDC	Mean PDC at 1y: 0.71
Jamaluddin et al (2019) (50)	Pakistan	Patients treated from August 2018 to January 2019 at a department of internal medicine	Hospital-based data	260	N.S	% adherent at 2 mo: 76.9%
Jermendy et al. (2018) (51)	Hungary	Patients starting with antidiabetic therapy from 1 January 2014 was followed until October 31, 2016	Database of the National Institute of Health Insurance Fund Management	27309 (treatment intensification cohort=26052; initial treatment cohort=1257)	Non-persistent: gap $\geq 180$ days	% persistent at 6 mo <sup>†</sup> : Intensification cohort: 77.2% % persistent at 1y: intensification cohort: 67.8% initial cohort: 59.6% % persistent at 2y: intensification cohort: 56.8% initial cohort: 47.0%

Lin et al. (2018) (52)	Taiwan	Patients prescribed medication from May 2016 to April	Data from 3 hospitals	597	N.S	% persistent at 1y: 72.1%
McGovern et al. (2018) (53)	UK	Patients dispensed diabetes medication between January 1, 2004 to January 1, 2015	Royal College of General Practitioners Research and Surveillance Centre (RCGP-RSC) database	1642	Non-persistent: gap $\geq 90$ days	% persistent at 6 mo: 79.5% % persistent at 1y: 69.5% % persistent at 2y: 54.8%
Ofori-Asenso et al. (2019) (54)	Australia	Adults aged 18 years and older with diabetes who initiated SGLT2 inhibitors between September 2015 and August 2017	Pharmaceutical benefits scheme (PBS)	11,981 (Dapagliflozin=5993; Empagliflozin=5988)	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-persistent: gap $\geq 90$ days	Mean PDC at 6 mo: Dapagliflozin: 0.82 $\pm$ 0.23 Empagliflozin: 0.86 $\pm$ 0.22 % adherent at 6mo: Dapagliflozin: 68.0% Empagliflozin: 76.3% % persistent at 6mo: Dapagliflozin: 82.9% Empagliflozin: 89.4% Mean PDC at 1y: Dapagliflozin: 0.75 $\pm$ 0.28 Empagliflozin: 0.81 $\pm$ 0.26 % Adherent at 1y: Dapagliflozin: 59.3% Empagliflozin: 69.4% % persistent at 1y: Dapagliflozin: 68.6% Empagliflozin: 73.3%
Singhal et al. (2018) (55)	USA	Patients dispensed canagliflozin between April 2013 and February 2016	HealthCore Integrated Research Database	750	Adherence assessed via PDC Adherent: PDC $\geq 0.80$ Non-Persistent (gap $\geq 90$ days)	% adherent at 1y: 47.5% % persistent at 1y: 50.4%
Woo et al. (2018) (56)	Canada	Patients enrolled in the Canadian multicenter, prospective cohort study	CANadian CANagliflozin REgistry (CanCARE)	527	N.S	% persistent at 1y: 82.1%
Wysham et al. (2018) (57)	USA	Patients who with prescription for canagliflozin on or after March 29, 2013	IQVIA™ Real-World Data Electronic Medical Records–US database	5540	Non-persistence: gap $\geq 90$ days	% persistent at 6 mo: 72.5% % persistent at 1y: 51.4% % persistent at 2y: 29.1%

<sup>†</sup>read from Kaplan meier graph; PDC=proportion of days covered; SGLT 2= sodium glucose co-transporter 2 inhibitors ; N.S= not specified

**Table 2:** Summary of the meta-analysis results of mean PDC, proportion adherent, and the proportion persistent at different follow-up periods

Outcome	Number of studies	Number of cohorts	Sample Size	Pooled results (95% CI)	<i>I</i> <sup>2</sup>
<b>Mean PDC</b>					
6 months	3*	5	30821	0.77 (0.72-0.82)	99.6%
1 y	3*	5	23875	0.72 (0.66-0.77)	99.6%
<b>% Adherent (PDC ≥0.80)</b>					
6 months	4	7	34667	59.5 (52.9-65.9)	99.2%
1 y	5	10	28808	49.0 (42.3-55.8)	99.2%
<b>% persistent</b>					
6 months					
All definitions	9	10	80894	80.1 (75.8-84.0)	99.4%


≥90-day gap	3	4	19163	81.5 (73.1-88.6)	99.5%
1 y					
All definitions	10	16	79181	61.8 (57.8-65.7)	99.2%
≥90-day gap	6	11	33729	58.9 (53.1-64.6)	99.1%
2 y					
All definitions	4	5	51510	45.9 (35.5-56.5)	99.8%
≥90-day gap	2	2	7182	34.7 (33.6-35.8)	0.0%

\*Some studies did not report standard deviation and therefore couldn't be included in the meta-analysis; PDC= proportion of days covered; CI= confidence interval

**Figure legends**

**Figure 1:** Flow chart of studies' selection process

Author Manuscript



DMRR\_3350\_Figure 1.tif